The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Second-line treatment in exon 11-mutated GIST patients: Imatinib dose escalation or sunitinib? Retrospective analysis of a multi-institutional experience.
Bruno Vincenzi
No relevant relationships to disclose
Margherita Nannini
No relevant relationships to disclose
Elena Fumagalli
No relevant relationships to disclose
Giuseppina Maltese
No relevant relationships to disclose
Anna Maria Frezza
No relevant relationships to disclose
Daniele Santini
No relevant relationships to disclose
Mariella Spalato Ceruso
No relevant relationships to disclose
Giuseppe Badalamenti
No relevant relationships to disclose
Maria A. Pantaleo
No relevant relationships to disclose
Paolo Giovanni Casali
No relevant relationships to disclose
Giuseppe Tonini
No relevant relationships to disclose